



April 11, 2018

DAILY *Links*

38th Annual Meeting & Scientific Sessions The Acropolis, Nice, France

Welcome to Nice from your Program Chair, Christian Benden

Finally, as our 2018 Annual Meeting is about to kick-off, it is an honor to see you again at the Palais des Congrès Nice Acropolis for the Society's 38th Annual Meeting and Scientific Sessions.

I hope you are looking forward as much as I do to an exciting week with rich discussions, healthy debates, and fun as well. We will build on the success of the 2017 San Diego Meeting, the best attended meeting in our Society's history. The Opening Plenary will kick off the meeting today Wednesday, followed by Symposia and Oral Abstract Sessions throughout the week, with content clustered as much as possible by specialty to facilitate the best use of attendees' time.

The plenary sessions will feature traditional content such as registry reports, the Presidential Address, and the Lifetime Achievement Award Laudation. In addition, research from the highest scoring abstracts is selected for featured presentations throughout plenary sessions to ensure the largest audience for our Annual Meeting's best scientific content. Further, in the Plenary Session on Friday morning entitled "Moving Cardiothoracic Transplantation Forward," the Keynote Speakers from Europe and North America will discuss "New Technologies to Advance Future Transplant Patient Care" and "Transplant Registries to Improve Results: It Relates to Research, Regulation, Reporting and Reimbursement." As food for thought, Professor Simon Hoerstrup from the Zurich Institute for Regenerative Medicine will address the topic of "Tissue-Engineered Matrix to Generate Organs."

The Closing Plenary Session sums up our Nice Meeting's basic and clinical science highlights and traditionally features the President's Debate. In Nice, debate contestants Gregory Snell from Melbourne and Howard Eisen from Philadelphia battle about the "DCDo's and DCDon'ts - We DCDo and We DCDon't." The two internationally highly regarded transplant physicians promise undoubtedly logical consistency and factual precision but also emotional appeal to the audience in their debate, certainly the program's climax and the perfect finish of a hopefully outstanding Annual Meeting.



OPENING PLENARY

Presidential Address

ISHLT President Andy Fisher, from Newcastle upon Tyne UK, will deliver his presidential address this morning as he concludes his presidential tenure within the Society.

We are extremely blessed that within ISHLT we have two key characteristics that underpin our society, in this address Dr. Fisher will define how we, as a society, will continue to protect and embrace these fundamental values of internationalism and multi-disciplinarity going forward.

These are exciting times for ISHLT as our membership and Annual Meeting continue to grow. Dr. Fisher will discuss how the ISHLT community is embracing areas of the world which have perhaps previously been neglected, and how we as a society can engage further with these communities to continue to deliver the highest level of education, research, and share our key aims in improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies.

Secondly, we must applaud our society that we are, and will continue to be a multi-disciplinary society. This address will challenge our thoughts to further develop this attribute and engage further with all disciplines involved in the care of advanced heart and lung disease. He will announce thrilling news regarding the launch of a brand new ISHLT website with smartphone friendly functionality to enable us to access **"ISHLT on the go"**. These innovative changes will enable fast access to state of the art research, as well increasing engagement to a far-reaching audience.


Abstract Presentations

Circumnavigating the world to attend conferences in glamorous locations is about many things. Of course, top of the list is sharing new information and results, which will directly impact how we manage our patients. With this in mind, the block-busting abstracts during the opening plenary surely will not disappoint. Prescribing medications used to prevent allograft rejection and balancing their associated deleterious side effects is one of the central aspects of our discipline. The German collaborative will present results of the breaking 4EVERLUNG trial – examining the impact of a quadruple immunosuppressive strategy to improve renal outcomes. Can Jens Gottlieb convince you to target tacrolimus at <5 ? The cardiac block-buster is the INTERHEART study – evaluation of a molecular diagnostic system for diagnosis of cardiac rejection at endomyocardial biopsy with respect to standard histology. Could the results change the way the cardiac allograft is evaluated?



*Wandering around in this old town,
searching for the truth...*

*we won't be a blockhead,
at the same time.*



French Origins of Scientific Societies, a few words from the editor

As the ISHLT improves as an academic and professional society, we continue to network and link new ideologies of science and medicine with a clear vision on humanism. Remnants of two 17th-century societies - The Royal Society of London and the Parisian Academy of Sciences - remain alive today. The contributions of these scientific academies before us sharpen our view on their importance to the practice and discovery of medicine. Today, our very own ISHLT is a byproduct of these international societies, especially relevant with our 2018 meeting this week near where these societies originated. As the ISHLT continues to transform as an academic society, we will continue to network and link new ideologies of science.

Some of the earliest societies were organized in Italy in the early 17th century. The most important was the Accademia dei Lincei (Academy of Lynxes), organized in Rome in 1603 by Frederico Cesi (1585–1630). Of course, yours truly here cannot resist the homonym lynx to the name of our newsletter, **The Links**.

The lynx belongs to the cat family and is among the larger felines known for their short stubby tails and long tufts of black hair on their ears. The name comes from Greek mythology about the character Lynceus whose eyesight was so sharp and piercing he could see through objects to find their **true** nature. The organizing members of the Accademia dei Lincie, named themselves the Lynxes because they were peering into the recesses of nature to unravel the **hidden truths** – sort of seeing through falsehoods to discover the **truth**. An outrageous and tangential link about this concept comes from the opening lyrics of a song from the “Transformers” soundtrack – “Before It’s Too Late”, by the Goo Goo Dolls –... “I wander through fiction to **look for the truth**, buried beneath all the lies...” Isn’t this what we do today with scientific inquiry in our society. This week, we are together, close to Italy in the south France, to share the latest ideas in search of the next **truths**.



Scientific societies played a key role in creating another home for scientific inquiry, in generating a public status for science and in linking scientific expertise with the state. Today, we have the ISHLT, an international and diverse society that serves to uncover the hidden truths applicable to our patients suffering from various heart and lung diseases who require replacement strategies or transformations, if you will.

View the full article from the April Links, Editor’s Corner [here](#).

Preview Symposium 04: Cardio-Oncology A Tale of Two Problems

Radiation and chemotherapy are not for the faint of heart. Nor are they good for the heart. So, what happens when these two worlds collide? Be sure to catch the

Wednesday afternoon symposium on the emerging specialty of cardio-oncology to learn more. Douglas Jennings, PharmD, will begin the discussion with the cardiotoxic risks of newer oncologic agents including the risk of fulminant myocarditis with checkpoint inhibitors. Next, Guilherme Oliveira, MD will share insight on the fine balance of oncologic efficacy with the cardiac complications of available treatments. Meike Rybczynski, MD will shed light on the management of cancer related cardiomyopathy with medical and mechanical therapies in a patient population already at increased risk of infection and coagulopathy. Next, Charles Canter, MD will discuss the role and timing of heart transplant in patients with an oncologic history as well as related post-transplant outcomes. Finally, Luciano Potena, MD, PhD, will review considerations for advanced therapies, including heart transplant, in patients with AL amyloidosis. You won't want to miss this hot topic discussion on cardio-oncology!

Oral Session 08: ECMO Management and Outcomes Four Liters and Fingers Crossed

Bridge to transplant. Bridge to LVAD. Bridge to recovery. Is ECMO the ultimate band-aid for cardiogenic failure? Are you interested in learning more about survival and neurological outcomes with temporary device support? If so, then don't miss this exciting discussion of several retrospective analyses looking at the management and outcomes associated with temporary devices. To begin the session, Benedikt Schrage, MD will discuss his experience with using percutaneous VAD support for left ventricular unloading in cardiogenic shock patients on VA ECMO. Next, Zubair Shah, MD will discuss interesting findings from a retrospective, multicenter database analysis on the use of ECMO as a bridge to heart transplant or LVAD in over 17,000 patients. Yi-Tso Cheng, MD will follow with a discussion of a retrospective review looking at long term outcomes in 158 patients who received ECMO or temporary VAD as a bridge to myocardial recovery and a potential surrogate for predicting three-year mortality. Next, Megan Kamath, MD will discuss a timely and interesting study on the improvement of survival outcomes in patients who receive ECMO as a bridge to heart transplant from three different eras. Omar Saeed, MD will then discuss a retrospective analysis looking at the association between thromboembolic stroke in VA ECMO patients and peak plasma free hemoglobin levels at 48 hours. Finally, Nicholas Cavarocchi, MD will end the session with a discussion on the use of near-infrared spectroscopy monitoring to predict neurological injury in ECMO patients. The future of ECMO in cardiogenic shock is here and you won't want to miss this informative session.


Preview Symposium 2: Planting a Flag on the Summit of Adult Congenital Heart Disease

Adult Congenital Heart disease patients offer us a new wave of challenges in the field of cardiac transplantation and MCS. Join us on Wednesday at 2pm in the Athena room as we explore the assessment and management of ACHD patients. This exciting symposium promises to bring together world experts in this field of complex patients. From the UK, Dr. David Crossland opens proceedings, exploring the increase in numbers of ACHD worldwide due to increased survival of these patients into adulthood. In this engaging talk he will discuss the need to review all options, not only transplant, for

these patients and highlight the world's largest series of patients with a systemic right ventricle bridged following transplant assessment with MCS.

The difficult question of when to refer these patients for assessment, and of course list them following assessment will be investigated as well, perhaps controversially as to whom!

Dr. Joseph Rossano then explores strategies to resuscitate the single ventricle patient in shock followed Dr. Lucy Roche from Toronto, Canada who then leads us to deliberate our thoughts when delving into non-transplant strategies for this cohort of patients, as well



as options to achieve transplant candidacy. Dr. Stephan Schubert delves into the significant co-morbidities these patients have and how these might limit heart alone transplant. This directs us onto discussions lead by Dr. Antonio Amodio from Rome, who challenges our thoughts and beliefs in surgical considerations of ACHD patients, including how seemingly impossible anatomical limitations of surgery can be addressed.

So, come and join us as we scale up the summit of ACHD.

Preview Oral Session 3: Novel Insights about Antibodies in Lung Transplantation

What better way to start today than with novel clinical research. From the ISHLT consensus document for AMR in 2016 comes a research session utilizing the consensus definitions put forward. The first presentation from the Baltimore group will indicate that 'probable' and 'possible' AMR may have a role in predicting the likely severity of disease and clinical course. Taking this further, their second presentation looks for markers of AMR (donor derived cell free DNA) to allow for preclinical identification. Who is likely to develop de-Novo DSA and AMR and how can we mitigate against this? Different aspects of this question will be evaluated by the Cleveland, Toronto and Washington groups.

Preview Mini Oral 5: Pediatric Thoracic Transplantation Young at Heart

Fortunately, dinner is served late in France, so all can stay to learn more about the latest research on pediatric thoracic transplantation during mini oral session 05. There will be a myriad of topics discussed with options for just about every clinical interest. There will be discussions around the new heart allocation system, outcomes of various lung and heart transplant populations, immunosuppression and mechanical support. Topics will move outside the thorax and include nutrition, the microbiome and novel technique utilizing virtual reality with the total artificial heart. These studies will be from single centers, databases and registries, and involve authors working together across institutions. There will be something for everyone during this session and it will be sure to excite those interested in the ongoing advancement of this field.

Plenary Session Live Stream Event

Join us live for our plenary sessions this week for stimulating conversations and lively debate. For free registration [click here](#).

Get More out of the Meeting with Tweeting! Use hashtag: #ISHLT2018

We encourage you to join our online conversations as we keep you up-to-date with the latest news, meeting information and events at this year's meeting.

Use **#ISHLT2018** when you share your favorite photos/videos, and connect with other attendees at the meeting.

If you have a Twitter account, follow us now! (@**ISHLT** or <https://twitter.com/ishlt>). If you want a Twitter account, visit www.twitter.com and create one FREE! Don't have an account? No worries! You can still search for #ISHLT2018 on Twitter and read what is posted.

Newsletter Editor:

Vincent Valentine, MD

Newsletter Coordinators:

Lauren Daniels and Naomi Rios

Roving Reporters:

Pediatric Heart Failure and Transplantation:

Adam Putschogl, DO

Mayo Clinic, Rochester, MN

Lung Failure and Transplantation:

Michael A. Trotter, MBChB, FRACP

The Prince Charles Hospital, Brisbane, Australia

Pharmacy and Pharmacology:

Cassandra Baker, PharmD, BCPS

Virginia Commonwealth University Health System

Nursing, Health Science, Allied Health:

Nicola Robinson, VAD Specialist Nurse

Freeman Hospital, Newcastle, UK

Disclaimer: Any opinion, conclusion or recommendation published by the Links is the sole expression of the writer(s) and does not necessarily reflect the views of the ISHLT.